BRCA1 is a luciferase-validated target of miR-182 (152,153) and miR-182 overexpression sensitized breast cancer cells to PARP inhibitors in vitro and in vivo via inhibition of BRCA1 (153). This evidence concerns the gene BRCA1 and breast cancer.